Supplementary Figure 2 - Cell viability assay for pediatric brain tumour lines exposed to the indicated concentrations of Veliparib, Olaparib, or Niraparib. from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma

A, MTT cell viability relative absorbance values across multiple cell lines after a 7-day incubation with Veliparib, Olaparib, or Niraparib. Boxes with an asterisk denote that an indicated concentration of PARP inhibitor significantly reduced cell viability relative vehicle treated cells. B, MTT cell viability heat map with numerical values. C, Linear regression analysis between PARP1 protein levels, relative to GAPDH, across all cell lines vs. IC50 values calculated from MTT viability assay on day 7. D, Linear regression analysis between PARP1 activity levels, relative to GAPDH, across all cell lines vs. IC50 values calculated from MTT viability assay on day 7. E, Different exposure of PARP1 Western blot in SJG2, SF188, 462, and 626 cells demonstrating variable PARP1 protein expression. *, **, ***, **** Denotes significance of p